Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Tesla Raises Cybertruck Prices by $5,000 in US 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Add as a preferred source on Google
WIXOM, Mich., May 02, 2018 -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold a conference call to discuss first quarter 2018 financial results on Thursday, May 10, 2018 at 4:30pm Eastern Time.
This call is also being webcast and can be accessed at the Rockwell Medical Investor Relations web page. You can join this call on:
| Date: | Thursday, May 10 |
| Time: | 4:30pm ET |
| Dial in number: | 866-548-4713 |
| International dial in: | 323-794-2093 |
| Passcode: | 3644040 |
| Webcast: | http://ir.rockwellmed.com |
About Rockwell Medical
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.
Rockwell’s recent FDA approved drug Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market and globally.
Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market.
Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three U.S. manufacturing/distribution facilities.
Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information.
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to sell and market Calcitriol and Triferic. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Triferic® is a registered trademark of Rockwell Medical, Inc.
Investor Contact:
Michael Rice
LifeSci Advisors
(646) 597-6979
[email protected]
Media Contact:
Matt Middleman
LifeSci Public Relations
(646) 627-8384
[email protected]
